Status:
COMPLETED
Assessing the Safety and Efficacy of FSD-F2R6-A-CP in Volunteers in an Induced State of Alcohol Intoxication
Lead Sponsor:
Quantum Biopharma
Conditions:
Acute Alcohol Intoxication
Eligibility:
All Genders
21-45 years
Phase:
NA
Brief Summary
This will be a (2 visit) double-blind, randomized, placebo crossover design clinical study to assess the potential benefits of FSD-F2R6-A-CP versus a placebo by assessing its impact on side effect pro...
Eligibility Criteria
Inclusion
- English-literate, non-smoking (\> 6 months),
- Men and women aged 25 to 45 years,
- Body mass index (BMI) of 18.5 to 32.0 kg/m2, and weighing between 110 and 220 lbs (50-100 kg).
- Free of the diseases listed in exclusion criteria according to their medical history,
- An ECG value of ≤ 440 msec for males and ≤ 460 msec for females, as measured by an FDA-cleared ECG device (6-lead device, KardiaMobile), administered by the investigator.
- Capable of consuming 4-6 standard drinks for women or 5-7 standard drinks for men on a single occasion without experiencing moderate sedation, vomiting, or aggression, to be eligible for the study. Moderate sedation is defined as the subject must be able to communicate and follow simple directions following the consumption of indicated number of drinks.
- Agree not to get tattoos or body piercings, or receive vaccines during the study period, or 7 days prior to the study period.
- Female subjects who must test negative on a urine pregnancy test, and cannot be pregnant or lactating. All subjects are required to either refrain from sex or use at least one form of contraception throughout the study, including a condom or either an oral or intrauterine contraceptive.
- Men who must agree not to donate sperm for 90 days following the trial.
- Experienced at least 2 hangovers
- Clinical laboratory values within the most recent acceptable laboratory test range, and/or values are deemed by the Investigator /Sub-Investigator as "Not Clinically Significant" as per CBC/CMP, urinalysis, and coagulation testing.
Exclusion
- A known history or presence of any clinically relevant conditions affecting the liver, kidneys, gastrointestinal system, cardiovascular system, cerebrovascular system, lungs, endocrine system, immune system, musculoskeletal system, nervous system, psychiatric state, respiratory system, skin, or blood, unless deemed not clinically significant by the Investigator/Sub-Investigator. This includes a significant history or current issues with gastrointestinal pathology, such as chronic diarrhea or inflammatory bowel diseases, or conditions affecting drug absorption, distribution, metabolism, or excretion
- Major surgery within the past 6 months, a history of seizures, significant head trauma, or neurosurgery, or any clinically significant illness within 30 days prior to dosing are also excluded
- Are on a ketogenic or very low carbohydrate diet within the past 30 days.
- Significant physical or organ abnormalities, a positive screening for a HIV, Hepatitis B or C (as determined by medical health questionnaires), or positive test result for drugs with abuse potential (cannabis, amphetamines, barbiturates, cocaine, opiates, phencyclidine and benzodiazepines)
- Alcohol-naïve
- Positive pregnancy test
- A history of significant alcohol sensitivity
- A history of adverse reactions to power (energy) drinks or caffeine,
- Severe food allergies, or dietary restrictions.
- Allergic reactions to any ingredients in the FSD-F2R6-A-CP and placebo.
- A psychiatric history of certain disorders, a first-degree relative with specific psychiatric or alcohol use disorders,
- An intolerance to blood sampling, recent blood or plasma donations within the past 60 days.
- Recently used enzyme-modifying drugs within the previous 30 days including strong inhibitors of cytochrome P450 (CYP) enzymes (e.g., cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP enzymes (e.g., barbiturates, carbamazepine, glucocorticoids, phenytoin, St. John's Wort, and rifampicin).
- Current or past history within the last 2 years of alcohol or drug dependence (excluding caffeine and nicotine).
- Current or past history within the last 5 years of major depressive disorder, obsessive-compulsive disorder, panic disorder, anorexia nervosa, or bulimia nervosa. First-degree relative with current or historical Alcohol Use Disorder (AUD).
- Intolerance to and/or difficulty with blood sampling through venipuncture or indwelling catheter.
- Used of prescription medication (other than contraception or occasional paracetamol) or over-the-counter medications including supplements within 14 days prior to session 1,
- A positive alcohol test at check-in on treatment day,
- Recent tattoos or piercings (within 7 days of study enrollment)
- Any condition deemed by the Investigator or Sponsor to interfere with study participation will be excluded.
Key Trial Info
Start Date :
July 12 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 7 2024
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT06505239
Start Date
July 12 2024
End Date
November 7 2024
Last Update
May 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Applied Science and Performance Institute
Tampa, Florida, United States, 33634